Fabris P, Marranconi F, Bozzola L, Biasin M R, De Lazzari F, Plebani M, Benedetti P, Tositti G, Pellizzer G, Stecca C, de Lalla F
Department of Infectious Diseases, S. Bortolo Hospital, Vicenza, Italy.
J Gastroenterol. 1999 Jun;34(3):345-50. doi: 10.1007/s005350050272.
The correlation between therapeutic response and liver fibrogenesis was studied in serum and liver specimens taken from 31 patients treated with alpha-interferon (IFN) (14 sustained responders and 17 non-responders) for chronic hepatitis C. Serum samples, collected before therapy, and at further 6-month intervals over 2 years, were tested for markers of liver neofibrogenesis. Serum N-terminal procollagen III peptide (PIIINP) displayed a significant and persistent decrease (P < 0.05) in sustained responders but not in non-responders; significantly lowered (P < 0.05) mean levels of C-terminal procollagen I peptide (PICP) were transiently observed in both patient groups, apparently as a result of IFN administration. Serum laminin (Lam) levels remained unchanged. One year after the cessation of treatment, liver biopsy re-testing showed an improvement in necro-inflammatory scores only in sustained responders, with the histological fibrosis scores remaining unaltered in both groups. IFN treatment seemed to exert an influence on serum levels of markers of hepatic connective tissue turnover even in patients that did not respond to therapy, while no effect was observed on preexistent liver fibrosis.
在31例接受α-干扰素（IFN）治疗的慢性丙型肝炎患者（14例持续应答者和17例无应答者）的血清和肝脏标本中，研究了治疗反应与肝纤维化形成之间的相关性。收集治疗前以及治疗后2年中每6个月的血清样本，检测肝脏新纤维形成的标志物。血清Ⅲ型前胶原N端肽（PIIINP）在持续应答者中呈现显著且持续的下降（P < 0.05），而在无应答者中则没有；在两个患者组中均短暂观察到Ⅰ型前胶原C端肽（PICP）的平均水平显著降低（P < 0.05），这显然是由于给予IFN所致。血清层粘连蛋白（Lam）水平保持不变。治疗停止一年后，肝脏活检复查显示仅在持续应答者中坏死性炎症评分有所改善，而两组的组织学纤维化评分均未改变。IFN治疗似乎对即使是无治疗反应患者的肝脏结缔组织更新标志物血清水平也有影响，而对已存在的肝纤维化则无作用。
